Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 52,437	$ 14,602
Prepaid expenses and other current assets	1,222	1,045
Total current assets	53,659	15,647
Long-term assets
Property and equipment, net	15	26
Operating lease right-of-use assets	474	131
Intangible assets, net	9,235	10,693
Other long-term assets	165
Total assets	63,548	26,497
Current liabilities
Accounts payable	3,216	1,777
Accrued compensation	1,498	1,675
Accrued clinical trial site costs	3,237	3,222
Common stock purchase liability	19,938
Operating lease liabilities - current	256	155
Other current liabilities	848	484
Total current liabilities	28,993	7,313
Long-term liabilities
Operating lease liabilities - noncurrent	214
Contingent liability for Essentialis purchase price	10,468	8,835
Total liabilities	40,328	16,149
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 15,467,229 and 8,159,382 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	15	8
Additional paid-in-capital	288,320	247,762
Accumulated deficit	(265,114)	(237,422)
Accumulated other comprehensive loss	(1)
Total stockholders’ equity	23,220	10,348
Total liabilities and stockholders’ equity	63,548	26,497
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 653	$ 1